Radiology, University of Wisconsin-Madison, 1111 Highland Ave, WIMR II, Room 2423, Madison, WI, 53705, USA.
Medical Physics, University of Wisconsin-Madison, Madison, WI, USA.
Abdom Radiol (NY). 2021 Aug;46(8):3708-3716. doi: 10.1007/s00261-021-03043-6. Epub 2021 Mar 23.
To evaluate the inter-reader reproducibility and prognostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (LR-TR) at the time of initial post-treatment evaluation following drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC).
This retrospective study included patients with HCC who underwent first-line DEB-TACE between January 2011 and December 2015. Six readers (three fellowship-trained radiologists and three radiology trainees) independently assessed lesion-level response in up to two treated lesions per LR-TR and modified Response Evaluation Criteria in Solid Tumors (mRECIST)-target criteria, as well as patient-level response per mRECIST-overall criteria, on the initial post-treatment CT/MRI. Inter-reader agreement was calculated by Fleiss' multi-reader κ. We tested whether LR-TR, mRECIST-target, and mRECIST-overall response were associated with overall survival using Kaplan-Meier and Cox proportional hazard model analyses.
A total of 82 patients with 113 treated target lesions were included. Inter-reader agreement was moderate for LR-TR and mRECIST-overall (κ range 0.42-0.57), and substantial for mRECIST-target (κ range 0.62-0.66), among all three reader-groups: all readers, experienced readers, and less-experienced readers. LR-TR and mRECIST-target response were not significantly associated with overall survival regardless of reader experience (P > 0.05). In contrast, mRECIST-overall response was significantly associated with overall survival when assessed by all readers (P = 0.02) and experienced readers (P = 0.03), but not by the less-experienced readers (P = 0.35).
Although LR-TR algorithm has moderate inter-reader reproducibility, it alone may not predict overall survival on the initial post-treatment CT/MRI after first-line DEB-TACE for HCC.
评估在经载药微球动脉化疗栓塞(DEB-TACE)治疗肝细胞癌(HCC)后初次治疗后评估时,使用 Liver Imaging Reporting and Data System(LI-RADS)治疗反应算法(LR-TR)的读者间重复性和预测准确性。
本回顾性研究纳入了 2011 年 1 月至 2015 年 12 月期间接受一线 DEB-TACE 治疗的 HCC 患者。6 名读者(3 名接受过 fellowship培训的放射科医生和 3 名放射科培训生)独立评估每个 LR-TR 最多 2 个治疗病灶的病变水平反应,以及根据改良实体瘤反应评价标准(mRECIST)-靶病灶标准的反应,以及 mRECIST-总体标准的患者水平反应,均在初次治疗后 CT/MRI 上进行。采用 Fleiss 多读者 κ 计算读者间一致性。我们使用 Kaplan-Meier 和 Cox 比例风险模型分析来检验 LR-TR、mRECIST-靶病灶和 mRECIST-总体反应与总生存的相关性。
共纳入了 82 名患者的 113 个治疗靶病灶。在所有三个读者组(所有读者、有经验的读者和经验较少的读者)中,LR-TR 和 mRECIST-总体的读者间一致性为中度(κ 范围 0.42-0.57),mRECIST-靶病灶的读者间一致性为高度(κ 范围 0.62-0.66)。LR-TR 和 mRECIST-靶病灶反应无论读者经验如何,与总生存均无显著相关性(P>0.05)。相反,所有读者(P=0.02)和有经验的读者(P=0.03)评估的 mRECIST-总体反应与总生存显著相关,但经验较少的读者(P=0.35)则无显著相关性。
尽管 LR-TR 算法具有中度的读者间可重复性,但在经一线 DEB-TACE 治疗 HCC 后初次 CT/MRI 上,其本身可能无法预测总生存。